Asset Details
Do you wish to reserve the book?
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Do you wish to request the book?
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
2014
Overview
Background
Standard therapies for high grade glioma have failed to substantially improve survival and are associated with significant morbidity. At relapse, high grade gliomas, such as glioblastoma multiforme, are refractory to therapy and universally fatal.
BRAF V600E
-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes. The use of
BRAF
inhibitors have transformed melanoma therapy however their use in brain tumors remains unproven.
Case presentation
We describe the pediatric case of a now 12 year old Caucasian male who originally presented at age 9 with a right fronto-parietal glioblastoma multiforme that recurred 2 ½ years from diagnosis. Molecular analysis of the primary tumor revealed a
BRAF V600E
mutation and the patient was placed on the
BRAF
inhibitor vemurafenib. A complete response was observed after 4 months of therapy and remains sustained at 6 months.
Conclusion
This is the first report of a complete response of relapsed glioblastoma multiforme to targeted
BRAF
inhibitor therapy. While not a predominant mutation in glioblastoma multiforme, the increased prevalence of
BRAF V600
mutations in pediatric CNS tumors and certain subtypes marks a population to whom this therapy could be applied. Response to this therapy suggests that BRAF inhibitors can affect primary CNS lesions when a documented and targetable mutation is present.
Publisher
BioMed Central,Springer Nature B.V
Subject
/ Child
/ Health Promotion and Disease Prevention
/ Humans
/ Indoles - administration & dosage
/ Male
/ Melanoma
/ Mutation
/ Neoplasm Recurrence, Local - drug therapy
/ Neoplasm Recurrence, Local - genetics
/ Neoplasm Recurrence, Local - pathology
/ Oncology
/ Proto-Oncogene Proteins B-raf - antagonists & inhibitors
/ Proto-Oncogene Proteins B-raf - genetics
/ Sulfonamides - administration & dosage
/ Tumors
